Comprehensive analysis of N 6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma

• Published in: Journal of clinical laboratory analysis Vol. 35; no. 12; p. e24071
• Main Authors: Zhu, Hong-Xu, Lu, Wen-Jie, Zhu, Wei-Ping, Yu, Song
• Format: Journal Article
• Language: English
• Published: United States 01.12.2021
• Subjects: Adenosine - analogs & derivatives; Adenosine - genetics; Aged; Biomarkers, Tumor - genetics; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - mortality; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Liver Neoplasms - mortality; Male; Middle Aged; Prognosis; Proportional Hazards Models; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology; N6-methyladenosine; long non-coding RNA; liver hepatocellular carcinoma; prognosis prediction
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.24071

Liver hepatocellular carcinoma (LIHC) is a lethal cancer. This study aimed to identify the N -methyladenosine (m A)-targeted long non-coding RNA (lncRNA) related to LIHC prognosis and to develop an m A-targeted lncRNA model for prognosis prediction in LIHC. The expression matrix of mRNA and lncRNA was obtained, and differentially expressed (DE) mRNAs and lncRNAs between tumor and normal samples were identified. Univariate Cox and pathway enrichment analyses were performed on the m A-targeted lncRNAs and the LIHC prognosis-related m A-targeted lncRNAs. Prognostic analysis, immune infiltration, and gene DE analyses were performed on LIHC subgroups, which were obtained from unsupervised clustering analysis. Additionally, a multi-factor Cox analysis was used to construct a prognostic risk model based on the lncRNAs from the LASSO Cox model. Univariate and multivariate Cox analyses were used to assess prognostic independence. A total of 5031 significant DEmRNAs and 292 significant DElncRNAs were screened, and 72 LIHC-specific m A-targeted binding lncRNAs were screened. Moreover, a total of 29 LIHC prognosis-related m A-targeted lncRNAs were obtained and enriched in cytoskeletal, spliceosome, and cell cycle pathways. An 11-m A-lncRNA prognostic model was constructed and verified; the top 10 lncRNAs included LINC00152, RP6-65G23.3, RP11-620J15.3, RP11-290F5.1, RP11-147L13.13, RP11-923I11.6, AC092171.4, KB-1460A1.5, LINC00339, and RP11-119D9.1. Additionally, the two LIHC subgroups, Cluster 1 and Cluster 2, showed significant differences in the immune microenvironment, m A enzyme genes, and prognosis of LIHC. The m A-lncRNA prognostic model accurately and effectively predicted the prognostic survival of LIHC. Immune cells, immune checkpoints (ICs), and m A enzyme genes could act as novel therapeutic targets for LIHC.